The Blood Testing Equipment Market is projected to grow from USD 3.2 billion in 2025 to over USD 4.4 billion by 2035, reflecting a CAGR of 3.2%.
This expansion is being supported by wider access to point-of-care diagnostics and increased demand for automated hematology and immunoassay testing systems across outpatient and decentralized care settings.
The adoption of compact diagnostic platforms in primary care and dental clinics has become more frequent. As per Nature Portfolio Journal in 2025, increasing frequency of general health screenings in dental practices is contributing to early detection of systemic diseases. The article highlights that "dental professionals are increasingly relying on automated testing instruments for blood diagnostics during routine care,” reinforcing the trend toward decentralized diagnostics.
Manufacturers are responding to these shifts by launching integrated, space-efficient testing systems. In January 2025, QIAGEN announced plans to expand its automation portfolio, with three new sample preparation platforms scheduled for release by 2026. The company stated in its press release that these systems are being designed to simplify workflows and reduce turnaround time, especially for medium-throughput laboratories.
| Metric | Value |
|---|---|
| Industry Size (2025E) | USD 3.2 billion |
| Industry Value (2035F) | USD 4.4 billion |
| CAGR (2025 to 2035) | 3.2% |
Automation and digital connectivity are becoming standard in new blood testing equipment. Key product requirements include minimal sample handling, improved traceability, and compatibility with laboratory information systems (LIS). These factors are particularly relevant in regional health centers where trained personnel may be limited.
In addition, the World Health Organization’s 2024 guidance on diagnostics in low-resource settings has recommended investment in automated blood testing platforms to improve disease surveillance and epidemic preparedness.
Advancements in reagent-free photometric detection and microfluidics are also reducing per-test costs. These developments have enabled small healthcare providers to adopt high-quality diagnostics without the need for extensive lab infrastructure. As healthcare systems continue to prioritize preventive care, compact blood analyzers are expected to play a pivotal role in early detection of conditions such as anemia, infections, and metabolic disorders.
Reagents & kits are projected to lead the global blood diagnostic equipment market, contributing approximately 39% of total market revenue in 2025. Over the forecast period from 2025 to 2035, this segment is expected to grow at a CAGR of 3.4%, marginally above the overall industry growth rate of 3.2%. The consistent and recurring demand for reagents in hematology, biochemistry, and immunoassays across high-throughput diagnostic environments continues to drive market expansion.
The increasing prevalence of chronic diseases such as diabetes, anemia, cardiovascular disorders, and infectious diseases has led to a rise in diagnostic procedures that rely on specific reagents and assay kits.
Additionally, advancements in reagent formulations-offering higher sensitivity, stability, and compatibility with multiple analyzer platforms-are improving diagnostic accuracy and operational efficiency. OEMs and third-party reagent suppliers are expanding their portfolios with disease-specific kits, automation-compatible cartridges, and dry chemistry reagents to serve both centralized and decentralized testing formats. Growth is further supported by the rising trend of bundled equipment and consumables in long-term procurement contracts across healthcare facilities.
Hospitals and clinics are expected to remain the dominant end-user segment, contributing approximately 41% of global market share in 2025, with the segment projected to grow at a CAGR of 3.3% through 2035.
These healthcare settings are the primary hubs for blood testing procedures ranging from routine screenings to emergency diagnostics and pre-operative evaluations.The expansion of hospital-based laboratory services, combined with rising patient inflow for chronic and acute conditions, has sustained the demand for in-house diagnostic equipment and consumables.
Additionally, integrated hospital information systems (HIS) and laboratory information systems (LIS) are enabling real-time data sharing, accelerating diagnostic workflows, and reducing turnaround times. Multispecialty hospitals are increasingly investing in high-throughput blood analyzers and POC devices to ensure rapid diagnostics in critical care units.
Challenges
Regulatory Hurdles Slowing Product Approvals
The introduction of new blood testing devices into the market is mainly affected by strict regulatory policies, for instance, the EU's IVDR and the USA FDA's changing compliance conditions. The complicated validation procedure can lead to a product approval delay of 12 to 24 months which, in turn, increases the costs for the manufacturers and makes fewer innovations available.
The requirement for extensive clinical trials and documentation is a great hindrance for the companies that are trying to come up with new testing technologies. Several start-ups deal with financial constraints in terms of fulfilling compliance requirements, thus making the market stagnant in terms of innovation. Nevertheless, regulatory authorities are looking at the possible adoption of adaptive approval pathways to alleviate the bottleneck.
High Cost of Advanced Testing Technologies
The blood testing devices with the latest technology like AI integrated haematology analysers along with molecular diagnostics often are pretty expensive. These costs act as a limiting factor in low-income areas where affordability remains a major issue. For instance, the molecular diagnostic platforms which number over the mark of USD 100,000 to secure them in small laboratories.
The endeavour of creating affordable options like paper-based diagnostics and smartphone-enabled blood tests is gaining momentum. But it is still a challenge to scale them while ensuring precision and quality assurance according to the government body's regulations. The industry partners are channelling resources into local assembly lines as a way to cut down costs and make products more affordable.
Opportunities
Expansion of Liquid Biopsy in Cancer Diagnostics
Liquid biopsy is becoming a revolutionary tool in the fight against cancer with the ability to detect the disease earlier through blood tests without surgery. Companies like Guardant Health and Roche have positioned themselves at The forefront of circulating tumor DNA (ctDNA) analysis which has proven over 85% accuracy in detecting multiple types of cancer. As precision oncology continues to develop, the demand for liquid biopsy technology will increase exponentially.
Regular usage in the clinic for instance, the elimination of certain biopsy types by liquid biopsy is the expectation that the latter will be recognized as the standard process thus leading to the decrease of discomfort of patients and the time taken for diagnosis. The increase in this type of technology during regular check-ups and treatment monitoring will be the prime mover in the blood testing tools market growth during the following ten years.
Wearable Biosensors for Continuous Monitoring
The emergence of wearable biosensors that can provide information about blood composition in real-time is creating diagnostic market opportunities. Wearable devices like glucose monitoring smartwatches and AI-integrated haemoglobin trackers are indicating a transformation in patient monitoring. Research work by Stanford University has shown that biosensors can observe metabolic variations long before the results of the normal laboratory tests are out, projecting 48 hours of lead time.
As the wearable devices empower, the integration of these biosensors with the telehealth platforms will provide personalized healthcare at the perimeter. Such breakthroughs will target the demand for monitoring devices using remote access, especially amongst the patient group with diabetes and cardiovascular diseases, thus heralding a new era of proactive diagnostics.
The increase in demand for personalized medicine and precision diagnostic techniques is the main factor affecting the USA blood testing equipment market. The growing use of telemedicine and home-based diagnostic solutions is making a monumental difference in patient care.
The further funding and partnership arrangement of biotech firms with healthcare companies are the reasons for innovation being boosted. The increase in use of molecular diagnostics has carried out the early detection and precise treatment of diseases. The market is also getting benefitted from the high occurrence of lifestyle diseases such as obesity and hypertension.
Market Growth Factors
| Country | CAGR (2025 to 2035) |
|---|---|
| USA | 5.3% |
The infusion of government initiatives mainly based on preventive health care, and early detection of diseases is the main reason for the rapid growth of the blood testing market of the United Kingdom. Use of the AI-based diagnostics instrument is streamlining the laboratory process and boosting the accuracy of testing.
The increasing public knowledge about the significance of health surveillance is the primary factor for the upsurge in home testing kits. The ongoing movement towards decentralized healthcare is the push factor for the establishment of many community diagnostic centers. Moreover, blood biomarker research investments are leading to the advent of non-invasive diagnostic technologies.
Market Growth Factors
| Country | CAGR (2025 to 2035) |
|---|---|
| UK | 5.9% |
Strict regulatory requirements related to quality and safety are the main driving factor for the EU market. The growing need for point-of-care testing in hospitals and clinics is robustly improving the speed of test and treatment decisions. The increasing share of the elderly population who suffer from age-related diseases like routine blood testing.
Environmentally friendly and waste-free medical devices are on the rise due to the implementation of stricter environmental rules. Furthermore, the strong public health system is the one that facilitates the access to diagnostic services.
Market Growth Factors
| Region | CAGR (2025 to 2035) |
|---|---|
| European Union | 6.2% |
Japan's blood testing equipment market is showing significant growth owing to the progress made in the field of compact and wearable diagnostic devices. The government's strong encouragement of the preventive health sector is elevating the incidence of testing for serious diseases. The concern with the automation of laboratories through robotics is enhancing the tempo and precision of tests. The requirements for COVID-19 protocols are driving the demand for quick and high-throughput diagnostic testing. In addition, the increasing funds flinging into the arena of regenerative medicine are facilitating the path for the development of cutting-edge blood therapies.
Market Growth Factors
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 6.5% |
The South Korean blood testing equipment sector is thriving amid the rapid digitalization process of the healthcare infrastructure. The government is earning praises for its active and positive engagement in supporting biotech startups, which in turn is promoting intra-entrepreneurship in the field of diagnosis. The increasing prevalence of blockchain technology has made it possible to manage medical data in a secure and transparent way that is ensuring diagnostic records safety. Also, the growing interest in personalized medicine has caused the need for specific and genetic blood tests to rise.
Market Growth Factors
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 5.5% |
Abbott Laboratories
Abbott Laboratories is the fastest point-of-care blood testing company that brings diagnostics closer to patients around the world. The company's i-STAT system is a widely-used hospital device for real-time results. The company discusses issues of affordability and accuracy and strongly emphasizes the integration of AI to achieve this. Lately, investments are concentrated in midstream markets throughout the world.
Roche Diagnostics
Roche Diagnostics dominates the AI-based blood analyzers and high-throughput testing platforms. It has started automated machines, as well as digital healthcare tools, as an extraordinary level to implement the systems. The group is directly involved by reducing reagent waste and promoting sustainability. Countering arrows to competition involve integrating the utilization of analytics that are based in the cloud and real time monitoring of blood tests.
Siemens Healthineers
Siemens Healthineers, through immunoassay and hematology analyzers, ensures accuracy of disease diagnosis. The company prioritizes AI-driven machine laboratory automation and precision medical care. It is seeing good traction in mature and emerging markets. New purchases have refurbished its capacity to tailor next-gen diagnostic tools for the particular needs of healthcare that are yet to be developed.
Danaher Corporation
Danaher Corporation is the molecular blood testing solutions provider with a distinctive logo of biomarker-based diagnostics. The company dedicates resources into tailor-made diagnostics that cater to the demands of precision medicine. The list of Danaher includes next-gen sequencing technology and tools for early disease detection. The company further expands through takeovers and strategic alliances.
Thermo Fisher Scientific
Thermo Fisher Scientific is a key player in laboratory-based blood diagnostics and reagent solutions. The company is the leader in clinical research tools and liquid biopsy innovations for the non-invasive testing market. It aims to improve early disease detection through its investment in precision medicine. Collateral strategic resources with health institutions are creating a stronger market presence.
Mid-sized and emerging firms have also contributed significantly in evolving blood testing technologies. These companies operate through specialized diagnostic equipment, which is more pocket-friendly, and by entering the untapped markets. Their contributions range from broadening product offerings to increasing access to novel testing solutions across various healthcare settings. A few such entities are:
The market is estimated to reach a value of USD 3.2 billion by the end of 2025.
The market is projected to exhibit a CAGR of 6.8% over the assessment period.
The market is expected to clock revenue of USD 4.4 billion by end of 2035.
Key companies in the Automated Test Equipment market include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Danaher Corporation, Thermo Fisher Scientific.
On the basis on end use, Hospitals & Clinics to command significant share over the forecast period.
Explore Medical & Biomedical Instruments Insights
Blood Testing Equipment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
